Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
ANTIHEMOPHILIC FACTOR (RECOMBINANT)
TAKEDA CANADA INC
B02BD02
COAGULATION FACTOR VIII
1000UNIT
POWDER FOR SOLUTION
ANTIHEMOPHILIC FACTOR (RECOMBINANT) 1000UNIT
INTRAVENOUS
2ML
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0124180002; AHFS:
APPROVED
2021-05-27
_ _ _ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] _ _Page 1 of 57_ PRODUCT MONOGRAPH ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (RAHF-PFM) 250, 500, 1000, 1500, 2000 AND 3000 INTERNATIONAL UNITS (IU) PER VIAL COAGULANT MANUFACTURED BY: Baxalta US Inc. Westlake Village, CA 91362 USA IMPORTED AND DISTRIBUTED BY: Baxalta Canada Corporation 7125 Mississauga Rd Mississauga, ON L5N 0C2 SUBMISSION CONTROL NO.: 182614 APPROVAL DATE: APRIL 21, 2014 _ _ _ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] _ _Page 2 of 57_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 DESCRIPTION................................................................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 4 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................. 12 OVERDOSAGE ............................................................................................................... 19 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 19 STORAGE AND STABILITY ......................................................................................... 21 SPECIAL HANDLING INSTRUCTIONS ....................................................... Կարդացեք ամբողջական փաստաթուղթը